211513-37-0 | Dalcetrapib

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$14.00	$10.00
5mg	95%	in stock	$40.00	$28.00
10mg	95%	in stock	$66.00	$46.00
25mg	95%	in stock	$132.00	$92.00
50mg	95%	in stock	$224.00	$157.00
100mg	95%	in stock	$435.00	$304.00
250mg	95%	in stock	$863.00	$604.00

Description

• Catalog Number: AF32565
• Chemical Name: Dalcetrapib
• CAS Number: 211513-37-0
• Molecular Formula: C23H35NO2S
• Molecular Weight: 389.5945
• MDL Number: MFCD06407886
• SMILES: CCC(CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C)CC

Computed Properties

• Complexity: 481
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 9
• XLogP3: 7.1

Literature

• Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.

  The Journal of pharmacology and experimental therapeutics 20150401

• Future of cholesteryl ester transfer protein inhibitors.

  Annual review of medicine 20140101

• Solubility and stability of dalcetrapib in vehicles and biological media.

  International journal of pharmaceutics 20121101

• Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat.

  Journal of cardiovascular pharmacology 20121001

• Tangier disease: epidemiology, pathophysiology, and management.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001

• Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

  Journal of lipid research 20120901

• Dalcetrapib , a cholesteryl ester transfer protein modulator.

  Expert opinion on investigational drugs 20120901

• Rationale for cholesteryl ester transfer protein inhibition.

  Current opinion in lipidology 20120801

• HDL and CETP Inhibition: Will This DEFINE the Future?

  Current treatment options in cardiovascular medicine 20120801

• Lipid and apoprotein composition of HDL in partial or complete CETP deficiency.

  Current vascular pharmacology 20120701

• Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20120701

• Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.

  European heart journal 20120701

• An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.

  Future cardiology 20120701

• Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.

  Current clinical pharmacology 20120501

• Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.

  Bioorganic & medicinal chemistry letters 20120501

• Dalcetrapib--restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease.

  Expert opinion on investigational drugs 20120401

• Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

  European heart journal 20120401

• Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates.

  European heart journal 20120401

• No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).

  International journal of clinical pharmacology and therapeutics 20120401

• Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: the dalcetrapib experience.

  Toxicology and applied pharmacology 20120315

• Pharmacotherapy. Elevating HDL-cholesterol levels with dalcetrapib is safe.

  Nature reviews. Cardiology 20120306

• On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.

  Drugs 20120305

• Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.

  American heart journal 20120301

• CETP inhibition in perspective.

  Atherosclerosis 20120201

• New horizons for cholesterol ester transfer protein inhibitors.

  Current atherosclerosis reports 20120201

• Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.

  Diabetes, obesity & metabolism 20120101

• Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations.

  PLoS computational biology 20120101

• Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.

  Nutrition & metabolism 20120101

• Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.

  Vascular health and risk management 20120101

• Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

  Core evidence 20120101

• Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

  Drug design, development and therapy 20120101

• Lipids, blood pressure, kidney - what was new in 2011?

  Archives of medical science : AMS 20111231

• [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].

  MMW Fortschritte der Medizin 20111208

• Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.

  Cardiovascular therapeutics 20111201

• Familial hypercholesterolemia: present and future management.

  Current cardiology reports 20111201

• Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.

  Journal of lipid research 20111201

• Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.

  Atherosclerosis 20111201

• Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?

  Trends in pharmacological sciences 20111201

• Therapy and clinical trials.

  Current opinion in lipidology 20111201

• Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.

  Expert opinion on investigational drugs 20111101

• Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

  Lancet (London, England) 20111029

• Dalcetrapib: turning the tide for CETP inhibition?

  Lancet (London, England) 20111029

• Anacetrapib: hope for CETP inhibitors?

  Cardiovascular therapeutics 20111001

• Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial.

  Nature reviews. Cardiology 20110927

• Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

  Current opinion in lipidology 20110801

• Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

  American heart journal 20110801

• Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.

  Current atherosclerosis reports 20110601

• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

  European heart journal 20110601

• Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.

  Clinical therapeutics 20110601

• [Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act 'A rebirth of hope'].

  Revista medica de Chile 20110601

• Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey.

  Xenobiotica; the fate of foreign compounds in biological systems 20110501

• Learning lessons from Pfizer's $800 million failure.

  Nature reviews. Drug discovery 20110301

• Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.

  Current medical research and opinion 20110101

• Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.

  The Annals of pharmacotherapy 20110101

• [Novel therapy for atherosclerosis and inflammatory vascular disease].

  Nihon rinsho. Japanese journal of clinical medicine 20110101

• Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.

  Clinical drug investigation 20110101

• Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

  Drug design, development and therapy 20110101

• Where are we heading with noninvasive clinical vascular physiology? Why and how should we assess endothelial function?

  Cardiology research and practice 20110101

• Emerging therapeutic strategies to enhance HDL function.

  Lipids in health and disease 20110101

• Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.

  Journal of lipid research 20101201

• Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.

  British journal of clinical pharmacology 20101201

• Good news for 'good' cholesterol.

  Nature 20101118

• Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.

  Journal of clinical pharmacology 20101001

• No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.

  Expert opinion on investigational drugs 20101001

• Emerging drugs for hyperlipidemia.

  Expert opinion on emerging drugs 20100901

• Biochemical characterization of cholesteryl ester transfer protein inhibitors.

  Journal of lipid research 20100901

• Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.

  Journal of hypertension 20100801

• Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.

  European journal of clinical pharmacology 20100801

• Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?

  Journal of hypertension 20100801

• Dissociating HDL cholesterol from cardiovascular risk.

  Lancet (London, England) 20100731

• Dalcetrapib: a review of Phase II data.

  Expert opinion on investigational drugs 20100601

• High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.

  Current pharmaceutical design 20100501

• Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381.

  Drugs in R&D 20100501

• MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages.

  Toxicology in vitro : an international journal published in association with BIBRA 20100401

• [HDL and CETP in atherogenesis].

  Deutsche medizinische Wochenschrift (1946) 20100201

• Functional assessment of HDL: Moving beyond static measures for risk assessment.

  Cardiovascular drugs and therapy 20100201

• Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

  European heart journal 20100201

• Mulling over the odds of CETP inhibition.

  European heart journal 20100201

• Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

  European heart journal 20100101

• Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.

  Journal of clinical lipidology 20100101

• Update on CETP inhibition.

  Journal of clinical lipidology 20100101

• Low high-density lipoprotein cholesterol: current status and future strategies for management.

  Vascular health and risk management 20100101

• High density lipoproteins-based therapies for cardiovascular disease.

  Journal of cardiovascular disease research 20100101

• Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.

  British journal of pharmacology 20091201

• Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

  American heart journal 20091201

• The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.

  The American journal of cardiology 20091116

• Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

  Journal of lipid research 20091101

• Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

  Expert opinion on therapeutic patents 20090901

• Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.

  Current opinion in investigational drugs (London, England : 2000) 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation.

  The Journal of biological chemistry 20090717

• The end of the road for CETP inhibitors after torcetrapib?

  Current opinion in cardiology 20090701

• Safety and tolerability of dalcetrapib.

  The American journal of cardiology 20090701

• In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.

  Current medical research and opinion 20090401

• A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.

  Clinical therapeutics 20090301

• Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.

  Thrombosis research 20090101

• JTT-705: is there still future for a CETP inhibitor after torcetrapib?

  Expert opinion on investigational drugs 20081001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080501

• Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?

  Expert opinion on investigational drugs 20080401

• Is raising HDL a futile strategy for atheroprotection?

  Nature reviews. Drug discovery 20080201

• HDL metabolism and CETP inhibition.

  Cardiology in review 20080101

• Gateways to clinical trials. July-August 2008.

  Methods and findings in experimental and clinical pharmacology 20080101

• The role of CETP inhibition in dyslipidemia.

  Current atherosclerosis reports 20070801

• The biology and chemistry of hyperlipidemia.

  Bioorganic & medicinal chemistry 20070715

• Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.

  Clinica chimica acta; international journal of clinical chemistry 20070101

• Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.

  European heart journal 20070101

• Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.

  Pharmacology & therapeutics 20060901

• Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.

  Current opinion in lipidology 20060801

• Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?

  Journal of molecular medicine (Berlin, Germany) 20060801

• Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.

  Current opinion in pharmacology 20060401

• Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.

  Journal of the American College of Cardiology 20060207

• Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?

  Current drug targets. Cardiovascular & haematological disorders 20051201

• JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways.

  Atherosclerosis 20051001

• Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.

  Arteriosclerosis, thrombosis, and vascular biology 20050901

• Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.

  Current opinion in cardiology 20050701

• Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.

  The American journal of cardiology 20050501

• Role of CETP inhibitors in the treatment of dyslipidemia.

  Current opinion in lipidology 20041201

• Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits.

  Arteriosclerosis, thrombosis, and vascular biology 20041001

• S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors.

  Bioorganic & medicinal chemistry letters 20040517

• JTT-705. Japan Tobacco.

  Current opinion in investigational drugs (London, England : 2000) 20040301

• Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits.

  Atherosclerosis 20040201

• Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells.

  American journal of physiology. Endocrinology and metabolism 20030601

• Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals.

  European journal of pharmacology 20030411

• Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.

  Arteriosclerosis, thrombosis, and vascular biology 20030201

• Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia.

  Clinical science (London, England : 1979) 20021201

• The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis.

  Clinical science (London, England : 1979) 20021201

• Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.

  Circulation 20020507

• Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage.

  Atherosclerosis 20020501

• [CETP inhibitor].

  Nihon rinsho. Japanese journal of clinical medicine 20010301